LCL521

LCL521 is a small molecule, lysosomotropic inhibitor of acid ceramidase (aCDase), an enzyme encoded by the ASAH1 gene that converts ceramide to sphingosine. By inhibiting aCDase, LCL521 leads to the accumulation of ceramide within lysosomes, which can subsequently be shunted toward sphingomyelin synthesis or induce apoptosis and sensitize cancer cells to other therapies. In the context of glioblastoma, LCL521 has been shown to modulate the sphingomyelin-ceramide balance in tumor-associated myeloid cells (TAMs), preventing their exhaustion and improving their capacity for antigen presentation and cell-cell communication. It was developed primarily in academic settings, notably at the Medical University of South Carolina, and is frequently used as a tool compound in preclinical oncology research.